Evidence map›Paper›PMID 28096163›Full record

ArticleAntimicrobial agents and chemotherapy2017

Large-Scale Evaluation of

George R Thompson, Bridget M Barker, Nathan P Wiederhold

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  3. Climate change and antimicrobial resistance.Nature reviews. Microbiology · 2026
    Review
  4. Manogepix demonstrates potentAntimicrobial agents and chemotherapy · 2026
    Article
  5. Rising burden of severe pediatric coccidioidomycosis: a 25-year single-center study.Journal of the Pediatric Infectious Diseases Society · 2026
    Observational
  6. Article
  7. Killing ofMicrobiology (Reading, England) · 2026
    Article
  8. Article
  9. Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025
    Review
  10. Insights into current coccidioidomycosis therapeutic pathways.Antimicrobial agents and chemotherapy · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Olorofim demonstratesAntimicrobial agents and chemotherapy · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Journal of fungi (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

George R ThompsonDepartment of Medicine, Division of Infectious Diseases, University of California-Davis Medical Center, Sacramento, California, USA grthompson@ucdavis.edu.
Bridget M BarkerPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.ORCID 0000-0002-3439-4517
Nathan P WiederholdFungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large-scale testing of

Indexed as

Amphotericin BAntifungal AgentsCaspofunginCoccidioidesCoccidioidomycosisEchinocandinsFlucytosineItraconazoleLipopeptidesMicrobial Sensitivity TestsTriazolesUnited StatesVoriconazoleAmphotericin BAntifungal AgentsCaspofunginEchinocandinsFlucytosineItraconazoleLipopeptidesposaconazoleTriazolesVoriconazoleamphotericin Bantifungal susceptibility testingcaspofunginCoccidioidescoccidioidomycosisendemic mycosesfluconazoleflucytosineitraconazoleposaconazolevoriconazole

Identifiers

PMID28096163
PMCPMC5365710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.